Hepatitis C

• 

  Subject Areas on Research

  • A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment. 
  • A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design. 
  • A flexible statistical model for alignment of label-free proteomics data--incorporating ion mobility and product ion information. 
  • A highly sensitive and specific enzyme-linked immunosorbent assay of antibodies to hepatitis C virus. 
  • A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. 
  • A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element. 
  • Acquired subretinal flecks secondary to hypovitaminosis A in a patient with hepatitis C. 
  • Activation and evasion of antiviral innate immunity by hepatitis C virus. 
  • Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study. 
  • All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. 
  • Altered m6A Modification of Specific Cellular Transcripts Affects Flaviviridae Infection. 
  • An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. 
  • An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. 
  • Analysis of site performance in academic-based and community-based centers in the IDEAL Study. 
  • Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. 
  • Antibodies against hepatitis C in a population of Swedish haemophiliacs and heterosexual partners. 
  • Antisense inhibitors, ribozymes, and siRNAs. 
  • Ascites in hepatitis C liver transplant recipients frequently occurs in the absence of advanced fibrosis. 
  • Association between hepatitis B virus and pancreatic cancer. 
  • Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. 
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 
  • Autoimmunity and HCV infection in porphyria cutanea tarda: a controlled study. 
  • Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization. 
  • Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance. 
  • Case of chronic eosinophilic leukemia with deletion of chromosome 16 and hepatitis C. 
  • Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. 
  • Chronic kidney disease in HIV infection: an urban epidemic. 
  • Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. 
  • Clinical hepatitis after transplantation of hepatitis C virus-positive kidneys: HLA-DR3 as a risk factor for the development of posttransplant hepatitis. 
  • Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. 
  • Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. 
  • Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. 
  • Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. 
  • Combined factor IX and XI deficiency discovered at liver biopsy. 
  • Community-based HCV screening: knowledge and attitudes in a high risk urban population. 
  • Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. 
  • Compliance with referral for hepatitis C evaluation among veterans. 
  • Concerted use of immunologic and ultrastructural analyses in diagnostic medicine: immunoelectron microscopy and correlative microscopy. 
  • Conjunctival pseudotumor caused by herpes simplex virus infection. 
  • Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment. 
  • Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0. 
  • Convergent evolution of escape from hepaciviral antagonism in primates. 
  • Cooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity. 
  • Cross-sectional survey of the extent and indicators of hepatitis C virus infection in Houston Department of Health and Human Services' sexually transmitted disease clinics. 
  • Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination. 
  • Current Management of Hepatitis C Virus Infection. 
  • Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. 
  • Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. 
  • Defining the spatial relationship between hepatitis C virus infection and interferon-stimulated gene induction in the human liver. 
  • Definition and management of anemia in patients infected with hepatitis C virus. 
  • Delayed liver fibrosis in HTLV-2-infected patients co-infected with HIV-1 and hepatitis C virus with suppressive antiretroviral therapy. 
  • Detection and Characterization of Human Pegivirus 2, Vietnam. 
  • Determining the Incidence of Hepatitis C Virus Infection in Populations: An Important Tool for Epidemic Control. 
  • Development of an HCV infection risk stratification algorithm for patients on chronic hemodialysis. 
  • Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. 
  • Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay. 
  • Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. 
  • Different cellular patterns associated with hepatitis C virus reactivation, cytomegalovirus infection, and acute rejection in liver transplant patients monitored with transplant aspiration cytology. 
  • Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. 
  • Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. 
  • Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. 
  • Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. 
  • Does this patient with liver disease have cirrhosis? 
  • Domino liver transplantation in maple syrup urine disease: a case report and review of the literature. 
  • Don't share razors or toothbrushes. 
  • Donor-derived hepatitis C in the era of increasing intravenous drug use: A report of the Disease Transmission Advisory Committee. 
  • Donor-derived hepatitis C transmission from NAT negative donors-Still an unexpected event! 
  • Drug resistance and HCV coinfection in former blood donors infected with HIV type 1 in China. 
  • Early experience with the use of hepatitis C antibody-positive, nucleic acid testing-negative donors in lung transplantation. 
  • Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. 
  • Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. 
  • Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. 
  • Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. 
  • Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. 
  • Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level. 
  • Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution. 
  • Elevated serum CA-125 levels: hepatitis or ascites? 
  • Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. 
  • Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. 
  • Emerging roles for lipid droplets in immunity and host-pathogen interactions. 
  • Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. 
  • Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. 
  • Eradicating hepatitis C: The need for a public health response. 
  • Evaluation for Fibrosis After Cure of Hepatitis C-Reply. 
  • Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy. 
  • Expanding the use of hepatitis C-viremic kidney donors. 
  • Factors influencing the participation of gastroenterologists and hepatologists in clinical research. 
  • Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. 
  • Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response. 
  • Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. 
  • Frequency and severity of HCV infection following orthotopic liver transplantation. Effect of donor and recipient serology for HCV using a second generation ELISA test. 
  • Future therapy of hepatitis C. 
  • Future trends in managing hepatitis C. 
  • GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? 
  • GBV-C in HIV-HCV coinfection, low liver-related mortality but high overall mortality. 
  • GBV-C/HGV is not the major cause of autoimmune hepatitis. 
  • Gender differences in hepatitis C infection and risks among persons with severe mental illness. 
  • Genetic variants of innate immune receptors and infections after liver transplantation. 
  • Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. 
  • Genotype 3 Infection: The Last Stand of Hepatitis C Virus. 
  • HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. 
  • HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. 
  • Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection. 
  • Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. 
  • Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. 
  • Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. 
  • Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. 
  • Hepatitis B and C viruses in infants and young children. 
  • Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. 
  • Hepatitis C Behind and Beyond Bars: Targeting the US Prison Population and Changing North Carolina Prisoner Health Policy. 
  • Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. 
  • Hepatitis C Treatment in Chronic Kidney Disease Patients: The Kidney Disease Improving Global Outcomes Perspective. 
  • Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. 
  • Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A. 
  • Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. 
  • Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. 
  • Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. 
  • Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. 
  • Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. 
  • Hepatitis C in Pregnancy: Review of Current Knowledge and Updated Recommendations for Management. 
  • Hepatitis C in pregnancy. 
  • Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there? 
  • Hepatitis C infection in children with hemophilia A and B. 
  • Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. 
  • Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. 
  • Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV. 
  • Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. 
  • Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. 
  • Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. 
  • Hepatitis C virus infection and the brain. 
  • Hepatitis C virus infection and the brain. 
  • Hepatitis C virus infection during pregnancy and the newborn period--are they opportunities for treatment? 
  • Hepatitis C virus infection--its role in pathogenesis. 
  • Hepatitis C virus infection. 
  • Hepatitis C virus infection. 
  • Hepatitis C virus infection: diagnosis, natural course and therapy. 
  • Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. 
  • Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. 
  • Hepatitis C. 
  • Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. 
  • High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. 
  • High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. 
  • Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. 
  • IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting. 
  • IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR. 
  • IL28B in the era of direct-acting antivirals for hepatitis C. 
  • Identification and comparative analysis of hepatitis C virus-host cell protein interactions. 
  • Impact of Cigarette Smoking Status on Pain Intensity Among Veterans With and Without Hepatitis C. 
  • Impact of donor and recipient hepatitis C status in lung transplantation. 
  • Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI cohort. 
  • Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013. 
  • Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury. 
  • Improved graft function in liver-transplanted patients after partial splenic embolization: reversal of splenic artery steal syndrome? 
  • Improving Hepatitis C Identification: Technology Alone Is Not the Answer. 
  • In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. 
  • In the clinic. Hepatitis C. 
  • Index of suspicion. 
  • Induction immunosuppression in liver transplantation: a review. 
  • Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. 
  • Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. 
  • Infectious complications in extended criteria heart transplantation. 
  • Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. 
  • Inhibition of hepatitis C viral RNA-dependent RNA polymerase by α-P-boranophosphate nucleotides: exploring a potential strategy for mechanism-based HCV drug design. 
  • Innovation, diffusion and safety of a medical technology: a review of the literature on injection practices. 
  • Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. 
  • Insights into antiviral innate immunity revealed by studying hepatitis C virus. 
  • Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. 
  • Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. 
  • Intrahepatic cholangiocarcinoma: new insights in pathology. 
  • Intrahepatic landscape of regulatory T-cell subsets in chronically HCV-infected patients with cirrhosis and HCC. 
  • Is the HCV pipeline heading in the right direction? 
  • Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. 
  • Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. 
  • Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis. 
  • Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors: a report from the Childhood Cancer Survivor Study. 
  • Live donor liver transplantation with older donors: Increased long-term graft loss due to HCV recurrence. 
  • Liver retransplantation: a single-center outcome and financial analysis. 
  • Liver transplantation in HIV/hepatitis co-infection. 
  • Liver transplantation in a patient coinfected with human immunodeficiency virus and hepatitis C virus. 
  • Long-term follow-up after successful interferon therapy of acute hepatitis C. 
  • Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. 
  • Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. 
  • Long-term outcome of hepatitis C virus infection after liver transplantation. 
  • Longer survival of liver transplant recipients with hepatitis virus coinfections. 
  • Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? 
  • Maximizing utilization of the donor pool by appropriate classification of hepatitis C antibody-positive donors. 
  • Measuring Hepatitis C Virus Envelopment by Using a Proteinase K Protection Assay. 
  • Membranoproliferative glomerulonephritis type I, mixed cryoglobulinemia and lymphoma in the absence of hepatitis C infection. 
  • Meningococcemia in a patient coinfected with hepatitis C virus and HIV. 
  • Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. 
  • Mixed model analysis of censored longitudinal data with flexible random-effects density. 
  • Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups. 
  • Mortality from sexually transmitted diseases in reproductive-aged women: United States, 1999-2010. 
  • Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images. 
  • NASH and cryptogenic cirrhosis: a histological analysis. 
  • Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. 
  • New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat. 
  • No significant influence of HLA determinants on susceptibility to hepatitis C virus infection in Caucasian patients with end-stage renal disease. 
  • Non-A, non-B hepatitis and chronic dialysis--another dilemma. 
  • Non-Hodgkin's lymphomas, version 1.2013. 
  • One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. 
  • Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. 
  • Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. 
  • Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. 
  • Overcoming barriers to care for hepatitis C. 
  • Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin. 
  • Partial splenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin. 
  • Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. 
  • Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. 
  • Pharmacogenetics at 50: genomic personalization comes of age. 
  • Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. 
  • Posttransplant B, non-A non-B, and cytomegalovirus hepatitis increase the risk of developing chronic rejection after liver transplantation. 
  • Predictors of proteinuria and renal failure among women with HIV infection. 
  • Pregnancy outcomes associated with viral hepatitis. 
  • Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. 
  • Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. 
  • Prevalence of non-A,non-B hepatitis/hepatitis C virus antibody in human immunoglobulins. 
  • Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients. 
  • Progression to cirrhosis in hepatitis C patients: an age-dependent process. 
  • Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. 
  • Proof of alleged transmission of hepatitis C virus by a conjunctival blood splash. 
  • Providing primary care for long-term survivors of childhood acute lymphoblastic leukemia. 
  • Pure red cell aplasia following pegylated interferon alpha treatment. 
  • Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness. 
  • Racial differences in hepatitis C treatment eligibility. 
  • Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C). 
  • Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong. 
  • Recurrent demyelinating myelitis associated with hepatitis C viral infection. 
  • Regular sources of medical care among persons with severe mental illness at risk of hepatitis C infection. 
  • Regulation of hepatic innate immunity by hepatitis C virus. 
  • Renal dysfunction in the setting of HIV/AIDS. 
  • Resection of hepatocellular carcinoma without cirrhosis. 
  • Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. 
  • Results of a pilot test of a brief computer-assisted tailored HIV prevention intervention for use with a range of demographic and risk groups. 
  • Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. 
  • Risk factors for HIV, hepatitis B, and hepatitis C among persons with severe mental illness. 
  • Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. 
  • Risks of a range of alcohol intake on hepatitis C-related fibrosis. 
  • Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. 
  • Safety and pharmacokinetics of lopinavir in HIV/HCV coinfected patients with advanced liver disease. 
  • Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. 
  • Secondary immunodeficiencies and stem cell transplantation: issues of administration and safety of intravenous immunoglobulin. 
  • Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. 
  • Serological pattern of hepatitis C virus recurrence after liver transplantation. 
  • Seroprevalence of hepatitis A, B, and C in a United States military recruit population. 
  • Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. 
  • Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. 
  • Shall we treat all patients with hepatitis C, and if not, why? Certainly, injecting drug users must not be an exclusion criterion. 
  • Shifting Away From Fee-For-Service: Alternative Approaches to Payment in Gastroenterology. 
  • Short and Long-Term Postoperative Complications Following Total Joint Arthroplasty in Patients With Human Immunodeficiency Virus, Hepatitis B, or Hepatitis C. 
  • Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. 
  • Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. 
  • Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. 
  • Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. 
  • Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure. 
  • Staphylococcus aureus pericardial abscess in a patient with liver cirrhosis: case report. 
  • Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. 
  • Streptococcus equi primary bacteremia in a hepatitis-C cirrhotic patient. 
  • Substance abuse and the transmission of hepatitis C among persons with severe mental illness. 
  • Successes and Challenges on the Road to Cure Hepatitis C. 
  • Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? 
  • Surveillance for hepatocellular carcinoma. 
  • Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. 
  • Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. 
  • Syringe exchanges: a public health response to problem drug use. 
  • The "PHS Increased Risk" Label Is Associated With Nonutilization of Hundreds of Organs per Year. 
  • The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. 
  • The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. 
  • The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. 
  • The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. 
  • The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. 
  • The five-site health and risk study of blood-borne infections among persons with severe mental illness. 
  • The hepatitis C crisis in the African American Community: findings and recommendations. 
  • The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam. 
  • The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. 
  • The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. 
  • The increasing impact of human immunodeficiency virus infections, sexually transmitted diseases, and viral hepatitis in Durham County, North Carolina: a call for coordinated and integrated services. 
  • The long-term course of hepatitis C after kidney transplantation. 
  • The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. 
  • The natural history of hepatitis C viral infection. 
  • The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation. 
  • The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment. 
  • Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. 
  • Transplant-associated autoimmune mechanisms in human hepatitis C virus infection. 
  • Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin. 
  • Treatment of acute hepatitis C infection: more pieces of the puzzle? 
  • Treatment of acute hepatitis C with interferon alfa-2b. 
  • Treatment of hepatitis C in special populations. 
  • Trends in health care resource use for hepatitis C virus infection in the United States. 
  • Tuberculosis complicating hepatitis C treatment in HIV-infected patients. 
  • Tuberculosis in solid organ transplant recipients at a tertiary hospital in the last 20 years in Barcelona, Spain. 
  • Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients. 
  • Ultrasound guided biopsy: what's new? 
  • Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. 
  • Virological and clinical characteristics of delta hepatitis in Central Europe. 
  • [Characteristics of hepatitis and influenza antivirals: update 2009]. 
  • [HIV infection in immigrants in Spain: Epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004-2006)]. 
  • [Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?]. 
  • [Virus associated glomerulonephritis]. 
  • gamma-Glutamyl transpeptidase as a response predictor when using alpha-interferon to treat hepatitis C. 
• 

  Keywords of People

  • Cunningham, Coleen Kathryn, Professor of Pediatrics, Pathology
  • Horner, Stacy M., Assistant Professor of Molecular Genetics and Microbiology, Duke Science & Society
  • Knechtle, Stuart Johnston, William R. Kenan, Jr. Distinguished Professor, Medicine, Nephrology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Muir, Andrew Joseph, Professor of Medicine, Medicine, Gastroenterology
  • Tsalik, Ephraim, Associate Professor of Medicine, Molecular Genetics and Microbiology
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine